(Q35216352)

7 August 2017

1 reference

title

Measuring the efficacy of antiepileptic drugs (English)

1 reference

7 August 2017

2

Martin J Brodie

0 references

author name string

Rajiv Mohanraj

series ordinal

1

1 reference

PubMed ID

12967570

7 August 2017

Martin J Brodie

series ordinal

2

1 reference

7 August 2017

1 October 2003

1 reference

Seizure-European Journal of Epilepsy

7 August 2017

1 reference

7 August 2017

12

1 reference

7 August 2017

7

1 reference

7 August 2017

413-443

1 reference

A proposed diagnostic scheme for people with epileptic seizures and with epilepsy: report of the ILAE Task Force on Classification and Terminology

7 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FS1059-1311%2803%2900047-5

7 January 2021

New antiepileptic drugs

1 reference

https://api.crossref.org/works/10.1016%2FS1059-1311%2803%2900047-5

7 January 2021

Management of epilepsy in adolescents and adults.

1 reference

https://api.crossref.org/works/10.1016%2FS1059-1311%2803%2900047-5

7 January 2021

Early identification of refractory epilepsy

1 reference

https://api.crossref.org/works/10.1016%2FS1059-1311%2803%2900047-5

7 January 2021

Do we need any more new antiepileptic drugs?

1 reference

https://api.crossref.org/works/10.1016%2FS1059-1311%2803%2900047-5

7 January 2021

Physicians' and patients' choices in evidence based practice

1 reference

https://api.crossref.org/works/10.1016%2FS1059-1311%2803%2900047-5

7 January 2021

The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomised trials

1 reference

https://api.crossref.org/works/10.1016%2FS1059-1311%2803%2900047-5

7 January 2021

Antiepileptic drugs, clinical trials, and the marketplace

1 reference

https://api.crossref.org/works/10.1016%2FS1059-1311%2803%2900047-5

7 January 2021

Systematic reviews and lifelong diseases

1 reference

https://api.crossref.org/works/10.1016%2FS1059-1311%2803%2900047-5

7 January 2021

Randomized trials or observational tribulations?

1 reference

https://api.crossref.org/works/10.1016%2FS1059-1311%2803%2900047-5

7 January 2021

Effectiveness of first antiepileptic drug.

1 reference

https://api.crossref.org/works/10.1016%2FS1059-1311%2803%2900047-5

7 January 2021

A double-blind trial of gabapentin monotherapy for newly diagnosed partial seizures. International Gabapentin Monotherapy Study Group 945-77.

1 reference

https://api.crossref.org/works/10.1016%2FS1059-1311%2803%2900047-5

7 January 2021

Topiramate, carbamazepine and valproate monotherapy: double-blind comparison in newly diagnosed epilepsy

1 reference

https://api.crossref.org/works/10.1016%2FS1059-1311%2803%2900047-5

7 January 2021

Monotherapy clinical trials of new antiepileptic drugs: design, indications, and controversies

1 reference

https://api.crossref.org/works/10.1016%2FS1059-1311%2803%2900047-5

7 January 2021

Hazards of inference: the active control investigation

1 reference

https://api.crossref.org/works/10.1016%2FS1059-1311%2803%2900047-5

7 January 2021

Is the underlying cause of epilepsy a major prognostic factor for recurrence?

1 reference

https://api.crossref.org/works/10.1016%2FS1059-1311%2803%2900047-5

7 January 2021

Does the cause of localisation-related epilepsy influence the response to antiepileptic drug treatment?

1 reference

https://api.crossref.org/works/10.1016%2FS1059-1311%2803%2900047-5

7 January 2021

A randomized, placebo-controlled study of topiramate in primary generalized tonic-clonic seizures. Topiramate YTC Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1059-1311%2803%2900047-5

7 January 2021

Meta-analysis of European placebo controlled studies of vigabatrin in drug resistant epilepsy

1 reference

https://api.crossref.org/works/10.1016%2FS1059-1311%2803%2900047-5

7 January 2021

Proof of efficacy trials: cross-over versus parallel-group

1 reference

https://api.crossref.org/works/10.1016%2FS1059-1311%2803%2900047-5

7 January 2021

Gabapentin and cognition: a double blind, dose ranging, placebo controlled study in refractory epilepsy

1 reference

https://api.crossref.org/works/10.1016%2FS1059-1311%2803%2900047-5

7 January 2021

The efficacy of valproate-lamotrigine comedication in refractory complex partial seizures: evidence for a pharmacodynamic interaction.

1 reference

https://api.crossref.org/works/10.1016%2FS1059-1311%2803%2900047-5

7 January 2021

The importance of drug interactions in epilepsy therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1059-1311%2803%2900047-5

7 January 2021

The new antiepileptic drugs: a systematic review of their efficacy and tolerability

1 reference

https://api.crossref.org/works/10.1016%2FS1059-1311%2803%2900047-5

7 January 2021

Selection of antiepileptic drug polytherapy based on mechanisms of action: the evidence reviewed

1 reference

https://api.crossref.org/works/10.1016%2FS1059-1311%2803%2900047-5

7 January 2021

Safety and efficacy of vigabatrin and carbamazepine in newly diagnosed epilepsy: a multicentre randomised double-blind study. Vigabatrin European Monotherapy Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1059-1311%2803%2900047-5

7 January 2021

Placebo-controlled trials and the Declaration of Helsinki

1 reference

https://api.crossref.org/works/10.1016%2FS1059-1311%2803%2900047-5

7 January 2021

Monotherapy comparative trials: placebos and suboptimal comparators

1 reference

https://api.crossref.org/works/10.1016%2FS1059-1311%2803%2900047-5

7 January 2021

Proof of efficacy trials: choosing the dose

1 reference

https://api.crossref.org/works/10.1016%2FS1059-1311%2803%2900047-5

7 January 2021

Monotherapy trials with the new antiepileptic drugs: study designs, practical relevance and ethical implications

1 reference

https://api.crossref.org/works/10.1016%2FS1059-1311%2803%2900047-5

7 January 2021

Monotherapy trials in antiepileptic drugs: are modified "presurgical studies" a way out of the dilemma?

1 reference

https://api.crossref.org/works/10.1016%2FS1059-1311%2803%2900047-5

7 January 2021

An active-control trial of lamotrigine monotherapy for partial seizures

1 reference

https://api.crossref.org/works/10.1016%2FS1059-1311%2803%2900047-5

7 January 2021

Monotherapy trial design: conversion versus de novo

1 reference

https://api.crossref.org/works/10.1016%2FS1059-1311%2803%2900047-5

7 January 2021

Active-Control Comparative Equivalency Monotherapy Trials in Epilepsy: Are They Scientifically Valid?

1 reference

https://api.crossref.org/works/10.1016%2FS1059-1311%2803%2900047-5

7 January 2021

The Ethical and Scientific Shortcomings of Current Monotherapy Epilepsy Trials in Newly Diagnosed Patients

1 reference

https://api.crossref.org/works/10.1016%2FS1059-1311%2803%2900047-5

7 January 2021

Trials to assess equivalence: the importance of rigorous methods

1 reference

https://api.crossref.org/works/10.1016%2FS1059-1311%2803%2900047-5

7 January 2021

Monotherapy comparative trials: equivalence and differences in clinical trials

1 reference

https://api.crossref.org/works/10.1016%2FS1059-1311%2803%2900047-5

7 January 2021

Monotherapy trials: sequential design

1 reference

https://api.crossref.org/works/10.1016%2FS1059-1311%2803%2900047-5

7 January 2021

Gabapentin versus lamotrigine monotherapy: a double-blind comparison in newly diagnosed epilepsy

1 reference

https://api.crossref.org/works/10.1016%2FS1059-1311%2803%2900047-5

7 January 2021

Proof of efficacy trials: endpoints

1 reference

https://api.crossref.org/works/10.1016%2FS1059-1311%2803%2900047-5

7 January 2021

Gabapentin as add-on therapy in refractory partial epilepsy: a double-blind, placebo-controlled, parallel-group study. The US Gabapentin Study Group No. 5

1 reference

https://api.crossref.org/works/10.1016%2FS1059-1311%2803%2900047-5

7 January 2021

Considerations on designing clinical trials to evaluate the place of new antiepileptic drugs in the treatment of newly diagnosed and chronic patients with epilepsy

1 reference

https://api.crossref.org/works/10.1016%2FS1059-1311%2803%2900047-5

7 January 2021

New antiepileptic drugs: a systematic review of their efficacy and tolerability

1 reference

https://api.crossref.org/works/10.1016%2FS1059-1311%2803%2900047-5

7 January 2021

Efficacy and Safety of Remacemide versus Carbamazepine in Newly Diagnosed Epilepsy: Comparison by Sequential Analysis.

1 reference

https://api.crossref.org/works/10.1016%2FS1059-1311%2803%2900047-5

7 January 2021

A method of quantification for the evaluation of antiepileptic drug therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1059-1311%2803%2900047-5

7 January 2021

The development of a seizure severity scale as an outcome measure in epilepsy

1 reference

https://api.crossref.org/works/10.1016%2FS1059-1311%2803%2900047-5

7 January 2021

The National Hospital Seizure Severity Scale: a further development of the Chalfont Seizure Severity Scale.

1 reference

https://api.crossref.org/works/10.1016%2FS1059-1311%2803%2900047-5

7 January 2021

Assessing the severity of seizures and epilepsy: which scales are valid?

1 reference

https://api.crossref.org/works/10.1016%2FS1059-1311%2803%2900047-5

7 January 2021

Quantitative assessment of seizure severity for clinical trials: a review of approaches to seizure components

1 reference

https://api.crossref.org/works/10.1016%2FS1059-1311%2803%2900047-5

7 January 2021

Development of a new seizure severity questionnaire: initial reliability and validity testing

1 reference

https://api.crossref.org/works/10.1016%2FS1059-1311%2803%2900047-5

7 January 2021

Commission on Outcome Measurement in Epilepsy, 1994-1997: final report

1 reference

https://api.crossref.org/works/10.1016%2FS1059-1311%2803%2900047-5

7 January 2021

Modern electroencephalography: its role in epilepsy management

1 reference

https://api.crossref.org/works/10.1016%2FS1059-1311%2803%2900047-5

7 January 2021

Absorption of diazepam from the rectum and its effect on interictal spikes in the EEG.

1 reference

https://api.crossref.org/works/10.1016%2FS1059-1311%2803%2900047-5

7 January 2021

The Delayed Effect of Sodium Valproate on the Photoconvulsive Response in Man

1 reference

https://api.crossref.org/works/10.1016%2FS1059-1311%2803%2900047-5

7 January 2021

Proof of principle trials: EEG surrogate endpoints

1 reference

https://api.crossref.org/works/10.1016%2FS1059-1311%2803%2900047-5

7 January 2021

The effect of lamotrigine, a novel anticonvulsant, on interictal spikes in patients with epilepsy

1 reference

https://api.crossref.org/works/10.1016%2FS1059-1311%2803%2900047-5

7 January 2021

Acute effects of lamotrigine (BW430C) in persons with epilepsy

1 reference

https://api.crossref.org/works/10.1016%2FS1059-1311%2803%2900047-5

7 January 2021

Lamictal (lamotrigine) monotherapy for typical absence seizures in children

1 reference

https://api.crossref.org/works/10.1016%2FS1059-1311%2803%2900047-5

7 January 2021

Valproate monotherapy in juvenile myoclonic epilepsy: dose-related effects on electroencephalographic and other neurophysiologic tests.

1 reference

https://api.crossref.org/works/10.1016%2FS1059-1311%2803%2900047-5

7 January 2021

Gabapentin as add-on therapy in focal epilepsy: a computerized EEG study.

1 reference

https://api.crossref.org/works/10.1016%2FS1059-1311%2803%2900047-5

7 January 2021

Effect of levetiracetam in patients with epilepsy and interictal epileptiform discharges

1 reference

https://api.crossref.org/works/10.1016%2FS1059-1311%2803%2900047-5

7 January 2021

Infantile spasms: diagnosis and assessment of treatment response by video-EEG.

1 reference

https://api.crossref.org/works/10.1016%2FS1059-1311%2803%2900047-5

7 January 2021

Monotherapy trials: endpoints

1 reference

https://api.crossref.org/works/10.1016%2FS1059-1311%2803%2900047-5

7 January 2021

A comparison of valproate with carbamazepine for the treatment of complex partial seizures and secondarily generalized tonic-clonic seizures in adults. The Department of Veterans Affairs Epilepsy Cooperative Study No. 264 Group

1 reference

https://api.crossref.org/works/10.1016%2FS1059-1311%2803%2900047-5

7 January 2021

Double-blind comparison of lamotrigine and carbamazepine in newly diagnosed epilepsy. UK Lamotrigine/Carbamazepine Monotherapy Trial Group

1 reference

https://api.crossref.org/works/10.1016%2FS1059-1311%2803%2900047-5

7 January 2021

The Neurotoxicity Scale: the validity of a patient-based scale, assessing neurotoxicity

1 reference

https://api.crossref.org/works/10.1016%2FS1059-1311%2803%2900047-5

7 January 2021

Multicentre, double-blind, randomised comparison between lamotrigine and carbamazepine in elderly patients with newly diagnosed epilepsy. The UK Lamotrigine Elderly Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1059-1311%2803%2900047-5

7 January 2021

Double-blind study of Gabapentin in the treatment of partial seizures.

1 reference

https://api.crossref.org/works/10.1016%2FS1059-1311%2803%2900047-5

7 January 2021

Gabapentin (Neurontin) as add-on therapy in patients with partial seizures: a double-blind, placebo-controlled study. The International Gabapentin Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1059-1311%2803%2900047-5

7 January 2021

High dose gabapentin in refractory partial epilepsy: clinical observations in 50 patients

1 reference

https://api.crossref.org/works/10.1016%2FS1059-1311%2803%2900047-5

7 January 2021

Safety and tolerability of gabapentin as adjunctive therapy in a large, multicenter study

1 reference

https://api.crossref.org/works/10.1016%2FS1059-1311%2803%2900047-5

7 January 2021

AUStralian study of titration to effect profile of safety (AUS-STEPS): high-dose gabapentin (neurontin) in partial seizures

1 reference

https://api.crossref.org/works/10.1016%2FS1059-1311%2803%2900047-5

7 January 2021

Topiramate placebo-controlled dose-ranging trial in refractory partial epilepsy using 200-, 400-, and 600-mg daily dosages. Topiramate YD Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1059-1311%2803%2900047-5

7 January 2021

Topiramate placebo-controlled dose-ranging trial in refractory partial epilepsy using 600-, 800-, and 1,000-mg daily dosages. Topiramate YE Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1059-1311%2803%2900047-5

7 January 2021

Double-blind, placebo-controlled study of topiramate in patients with refractory partial epilepsy

1 reference

https://api.crossref.org/works/10.1016%2FS1059-1311%2803%2900047-5

7 January 2021

Double-blind, placebo-controlled trial of topiramate (600 mg daily) for the treatment of refractory partial epilepsy

1 reference

https://api.crossref.org/works/10.1016%2FS1059-1311%2803%2900047-5

7 January 2021

Double-blind, placebo-controlled trial of topiramate as add-on therapy in patients with refractory partial seizures

1 reference

https://api.crossref.org/works/10.1016%2FS1059-1311%2803%2900047-5

7 January 2021

Topiramate in refractory epilepsy: a prospective observational study

1 reference

https://api.crossref.org/works/10.1016%2FS1059-1311%2803%2900047-5

7 January 2021

Topiramate in patients with learning disability and refractory epilepsy

1 reference

https://api.crossref.org/works/10.1016%2FS1059-1311%2803%2900047-5

7 January 2021

Flunarizine for treatment of partial seizures: results of a concentration-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS1059-1311%2803%2900047-5

7 January 2021

Double-blind crossover trial of lamotrigine (Lamictal) as add-on therapy in intractable epilepsy.

1 reference

https://api.crossref.org/works/10.1016%2FS1059-1311%2803%2900047-5

7 January 2021

Efficacy and safety of zonisamide: results of a multicenter study.

1 reference

https://api.crossref.org/works/10.1016%2FS1059-1311%2803%2900047-5

7 January 2021

Safety and efficacy of divalproex sodium monotherapy in partial epilepsy: a double-blind, concentration-response design clinical trial. Depakote Monotherapy for Partial Seizures Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1059-1311%2803%2900047-5

7 January 2021

Concentration--effect and concentration--toxicity relations with lamotrigine: a prospective study

1 reference

https://api.crossref.org/works/10.1016%2FS1059-1311%2803%2900047-5

7 January 2021

Assessing quality of life in patients with epilepsy

1 reference

https://api.crossref.org/works/10.1016%2FS1059-1311%2803%2900047-5

7 January 2021

The initial development of a health-related quality of life model as an outcome measure in epilepsy.

1 reference

https://api.crossref.org/works/10.1016%2FS1059-1311%2803%2900047-5

7 January 2021

Development of the quality of life in epilepsy inventory.

1 reference

https://api.crossref.org/works/10.1016%2FS1059-1311%2803%2900047-5

7 January 2021

Seizure reduction and quality of life improvements in people with epilepsy

1 reference

https://api.crossref.org/works/10.1016%2FS1059-1311%2803%2900047-5

7 January 2021

Adjunctive lamotrigine therapy in patients with refractory seizures: a lifetime cost-utility analysis

1 reference

https://api.crossref.org/works/10.1016%2FS1059-1311%2803%2900047-5

7 January 2021

Pros and cons for the development of new antiepileptic drugs.

1 reference

https://api.crossref.org/works/10.1016%2FS1059-1311%2803%2900047-5

7 January 2021

Randomised, placebo-controlled study of vigabatrin as first-line treatment of infantile spasms

1 reference

https://api.crossref.org/works/10.1016%2FS1059-1311%2803%2900047-5

7 January 2021

Postmarketing surveillance of new antiepileptic drugs: the tribulations of trials

1 reference

https://api.crossref.org/works/10.1016%2FS1059-1311%2803%2900047-5

7 January 2021

The value of the number-needed-to-treat method in antiepileptic drug trials

1 reference

https://api.crossref.org/works/10.1016%2FS1059-1311%2803%2900047-5

7 January 2021

Carbamazepine versus valproate monotherapy for epilepsy: a meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS1059-1311%2803%2900047-5

7 January 2021

10.1016/S1059-1311(03)00047-5

Identifiers

DOI

1 reference

7 August 2017

1 reference

PubMed ID

12967570